Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 15.36M P/E - EPS this Y 55.30% Ern Qtrly Grth -
Income -20.48M Forward P/E -0.79 EPS next Y 90.50% 50D Avg Chg 16.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 42.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -63.00%
Recommedations 1.00 Quick Ratio 0.20 Shares Outstanding 3.14M 52W Low Chg 317.00%
Insider Own 0.41% ROA -73.24% Shares Float 2.78M Beta 2.73
Inst Own 18.53% ROE - Shares Shorted/Prior 21.49K/33.78K Price 7.09
Gross Margin - Profit Margin - Avg. Volume 1,229,174 Target Price 30.00
Oper. Margin - Earnings Date Mar 29 Volume 155,729 Change 13.26%
About Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

Eloxx Pharmaceuticals, Inc. News
03/13/24 Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
12/05/23 Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor
11/13/23 Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
10/09/23 Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
09/19/23 Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
09/18/23 Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
09/07/23 Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
08/14/23 Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
08/03/23 Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
07/10/23 Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit
08:00 AM Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02
06/21/23 Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome
06/21/23 Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress
06/14/23 Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients
06/01/23 Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer
05/24/23 Eloxx Pharmaceuticals Plans To Take ELX-02 Into Pivotal Trial For Alport Syndrome
05/24/23 Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study
05/15/23 Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
05/02/23 Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013
04/03/23 Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update
ELOX Chatroom

User Image Abjo Posted - 8 hours ago

$ELOX and $ZJYL Doing my DD

User Image Trident1014 Posted - 1 day ago

$ELOX What are we up to?

User Image MEDIUMSPACY Posted - 1 week ago

$ELOX

User Image JodyDurham Posted - 2 weeks ago

$ELOX rotate out 778,646. Has the sleeper awoken?

User Image Yourmatefromdownunder Posted - 2 weeks ago

$ELOX Been buying all day.

User Image JodyDurham Posted - 2 weeks ago

$ELOX https://investors.eloxxpharma.com/news-releases/news-release-details/almirall-and-eloxx-pharmaceuticals-enter-exclusive-agreement

User Image JodyDurham Posted - 2 weeks ago

$ELOX amazing news "As part of this agreement, Eloxx will receive an upfront of $3 million, and additional payments throughout the potential development phases, including regulatory and sales milestones of up to $470 million, as well as tiered royalties based on any potential future global sales."

User Image MEDIUMSPACY Posted - 2 weeks ago

$ELOX

User Image rcord Posted - 2 weeks ago

$ELOX

User Image Stocks4thought Posted - 2 weeks ago

$ELOX once was dope- they gonna get re-listed?

User Image Trident1014 Posted - 2 weeks ago

$ELOX On a run

User Image Trident1014 Posted - 1 month ago

$ELOX Let's go

User Image DonCorleone77 Posted - 2 months ago

$ELOX Eloxx Pharmaceuticals files to sell 778,646 shares of common stock for holders

User Image YearOfTheRabbit Posted - 2 months ago

$ELOX so what haopened ?

User Image Ninja_Tradez Posted - 2 months ago

TOP LOSERS FROM MARKET OPEN $JTAIZ | Price: 0.3301 | $ Change: -0.5299 | % Percent: -61.6163% $VRM | Price: 0.3028 | $ Change: -0.225 | % Percent: -42.6298% $NUTX | Price: 0.1387 | $ Change: -0.0489 | % Percent: -26.0661% $AGFY | Price: 0.6911 | $ Change: -0.1869 | % Percent: -21.287% $ELOX | Price: 0.89 | $ Change: -0.22 | % Percent: -19.8198%

User Image Ninja_Tradez Posted - 2 months ago

TOP LOSERS FROM MARKET OPEN $VRM | Price: 0.3287 | $ Change: -0.1991 | % Percent: -37.7226% $ELOX | Price: 0.75 | $ Change: -0.36 | % Percent: -32.4324% $NUTX | Price: 0.14 | $ Change: -0.0476 | % Percent: -25.3731% $REVB | Price: 0.3204 | $ Change: -0.0996 | % Percent: -23.7143% $KRBP | Price: 1.41 | $ Change: -0.43 | % Percent: -23.3696%

User Image Justonks Posted - 2 months ago

$ELOX pump it to 8 so I can get out 😂 eyeeyeye

User Image Resurrected_Magic Posted - 2 months ago

$OPK saw this set up with $VBIV and $COCP $ELOX and $RGTPQ Bagholders say, no way Frost would issue options as a scam. It will rebound. Nope. Honig and Brauser et al are driving it down and then Frost will sell it to himself and issue new shares. Giant 40 year pump and dump scam Federal prison now!

User Image Last10K Posted - 2 months ago

$ELOX just filed with the SEC a New Agreement and a Unregistered Sales https://last10k.com/sec-filings/ELOX/0001104659-24-002631.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=ELOX

User Image risenhoover Posted - 2 months ago

$ELOX / Eloxx Pharmaceuticals files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 Eloxx Pharmaceuti https://fintel.io/doc/sec-eloxx-pharmaceuticals-inc-1035354-8k-2024-january-09-19731-4633?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image Stockchooser Posted - 2 months ago

$ELOX 🔥🚀⬆️

User Image Last10K Posted - 3 months ago

$ELOX just filed with the SEC a Event for Officers and a Financial Exhibit https://last10k.com/sec-filings/ELOX/0001104659-23-130052.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=ELOX

User Image risenhoover Posted - 3 months ago

$ELOX / Eloxx Pharmaceuticals files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2023 Eloxx Pharmaceu https://fintel.io/doc/sec-eloxx-pharmaceuticals-inc-1035354-8k-2023-december-28-19719-5611?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image MEDIUMSPACY Posted - 3 months ago

$ELOX

User Image StockMvis Posted - 3 months ago

$ELOX scam

User Image Last10K Posted - 3 months ago

$ELOX just filed with the SEC a New Agreement and a New Financial Obligation https://last10k.com/sec-filings/ELOX/0001104659-23-126400.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=ELOX

User Image risenhoover Posted - 3 months ago

$ELOX / Eloxx Pharmaceuticals files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 Eloxx Pharmaceu https://fintel.io/doc/sec-eloxx-pharmaceuticals-inc-1035354-8k-2023-december-15-19706-8091?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image Alvliv21 Posted - 3 months ago

$ELOX https://finance.yahoo.com/news/off-beaten-path-3-delisted-134819764.html

User Image I_hate_VKTX Posted - 3 months ago

User Image I_hate_VKTX Posted - 3 months ago

$ELOX this is the future of $vktx

Analyst Ratings
Oppenheimer Outperform Jul 11, 23
Oppenheimer Outperform Apr 6, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Nussbaum Ran Director Director May 17 Buy 1.35 5,925,925 7,999,999 616,592 05/17/21
Kariv Tomer Director Director May 17 Buy 1.35 5,925,925 7,999,999 616,592 05/17/21